Pipeline Watch: Five Approvals And 28 Phase III Updates
The Week In R&D
Executive Summary
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
You may also be interested in...
Top 10 Best-Selling Drugs Of Q2 2023: COVID-19 Out, HPV In
The Merck & Co vaccine for human papillomavirus Gardasil, along with Johnson & Johnson’s Darzalex for multiple myeloma, entered the ranks of the top 10 best-selling drugs globally in the second quarter. There was no product for COVID-19 in the line-up for the first time since 2020.
Can Medicare Cover Obesity Drugs Without Congressional Action? Industry Builds Its Case
Obesity drug ≠ weight-loss drug, a new Pfizer-funded white paper argues in laying out a legal case for Part D coverage of obesity medicines even without legislation. Advocates hope forthcoming updates to a 2007 FDA guidance on weight management drugs will bolster the case for coverage.
What’s Next? Five Things To Look Out For In October
Generics Bulletin previews the most notable and anticipated events for October 2023.